Chemo Brain (Chemo Fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction

Christopher D. Aluise, Rukhsana Sultana, Jitbangjong Tangpong, Mary Vore, Daret St. Clair, Jeffrey A. Moscow, D. Allan Butterfield

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

84 Scopus citations

Abstract

Doxorubicin (ADRIAMYCIN, RUBEX) is a chemotherapeutic agent that is commonly administered to breast cancer patients in standard chemotherapy regimens. As true of all such therapeutic cytotoxic agents, it can damage normal, noncancerous cells and might affect biochemical processes in a manner that might lead to, or contribute to, chemotherapy-induced cognitive deficits when administered either alone or in combination with other agents.

Original languageEnglish
Title of host publicationChemo Fog
Subtitle of host publicationCancer Chemotherapy-Related Cognitive Impairment
EditorsRobert Raffa, Ronald Tallarida
Pages147-156
Number of pages10
DOIs
StatePublished - 2010

Publication series

NameAdvances in Experimental Medicine and Biology
Volume678
ISSN (Print)0065-2598

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (all)

Fingerprint

Dive into the research topics of 'Chemo Brain (Chemo Fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction'. Together they form a unique fingerprint.

Cite this